$IMNN

Imunon, Inc.

Imunon is a clinical-stage biotechnology company developing treatments that use non-viral DNA technology. Its platform delivers DNA and mRNA therapeutics using synthetic carriers. The TheraPlas modality is designed to encode proteins and cytokines for solid tumors, while PlaCCine is designed to encode viral antigens for potential vaccines against infectious diseases. Imunon’s lead program, IMNN-001, is a DNA-based immunotherapy for localized treatment of advanced ovarian cancer, being studied with standard chemotherapy. The company is also developing IMNN-101, a COVID-19 booster vaccine, and has completed dosing in its first-in-human study. Imunon makes money through development and potential commercialization of its drug candidates and technology, directly or through partnerships. It is headquartered in Lawrenceville, New Jersey.

2
0
2

No SEC Form 4 filings for $IMNN in the last 30 days.

See all $IMNN insider activity →
Med

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

IMNN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning IMNN (Imunon, Inc.). Coverage has been balanced: 2 bullish, 0 neutral, and 2 bearish.

Recent IMNN coverage spans corporate actions, earnings and technology.

What's driving IMNN

AlphAI scores every news story that mentions IMNN with an AI model for sentiment and relevance, and aggregates insider trades from Imunon, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMNN

Score

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNHighAI 8/10Earnings

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

Biotech Stocks Move Higher: IMNN Surges Over 18%, HSCS Gains Over 13%, SXTC Rises 7%

China SXT Pharmaceuticals (SXTC) rose 7% after terminating an additional purchase right tied to its recent offering. Imunon (IMNN) surged 18% following a deal to sell ThermoDox rights, potentially receiving $16.5M in milestone payments. HeartSciences (HSCS) gained 13% after filing a proxy statement for a proposed merger with Fortitude Mining, creating a digital asset mining platform.

$IMNNMedM&A· acquirer · $16.5M · announced

Imunon, Inc. (IMNN): Entry into a Material Definitive Agreement

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 IMUNON Announces Strategic Sale of ThermoDox® Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON’s Commitment to Its Core S

$IMNNLowOffering· 120 · proposed

Imunon, Inc. (IMNN): Entry into a Material Definitive Agreement

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and t

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.

Imunon, Inc. (IMNN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Compensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory

Related tickers